Dean Messing

694 total citations
14 papers, 281 citations indexed

About

Dean Messing is a scholar working on Molecular Biology, Immunology and Organic Chemistry. According to data from OpenAlex, Dean Messing has authored 14 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Immunology and 4 papers in Organic Chemistry. Recurrent topics in Dean Messing's work include Melanoma and MAPK Pathways (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Synthesis and biological activity (3 papers). Dean Messing is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Synthesis and biological activity (3 papers). Dean Messing collaborates with scholars based in United States and Japan. Dean Messing's co-authors include Larry C. Wienkers, Rajesh Devraj, Shaun R. Selness, Mark E. Schnute, Joseph B. Monahan, Elizabeth Webb, Gary D. Anderson, Steven L. Settle, T. Sunyer and Olga V. Nemirovskiy and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Dean Messing

14 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dean Messing United States 10 139 62 60 55 41 14 281
Lisa Borges-Marcucci Canada 8 98 0.7× 50 0.8× 23 0.4× 172 3.1× 60 1.5× 9 403
Daigo Asano Japan 9 140 1.0× 25 0.4× 18 0.3× 72 1.3× 53 1.3× 19 527
Janice Darlington Türkiye 12 293 2.1× 82 1.3× 15 0.3× 36 0.7× 21 0.5× 16 490
Denise M. Wilcox United States 6 128 0.9× 110 1.8× 17 0.3× 36 0.7× 22 0.5× 8 338
Shaun R. Selness United States 10 206 1.5× 114 1.8× 15 0.3× 54 1.0× 50 1.2× 12 359
Elena Dneprovskaia United States 10 204 1.5× 90 1.5× 14 0.2× 57 1.0× 20 0.5× 11 408
Hailin Chen China 8 104 0.7× 27 0.4× 38 0.6× 109 2.0× 12 0.3× 24 288
Chengcan Yang China 11 263 1.9× 39 0.6× 13 0.2× 74 1.3× 48 1.2× 14 368
Ellen van der Aar Belgium 11 144 1.0× 61 1.0× 96 1.6× 46 0.8× 36 0.9× 22 342
Mary D. Adrian United States 12 166 1.2× 177 2.9× 15 0.3× 109 2.0× 50 1.2× 18 613

Countries citing papers authored by Dean Messing

Since Specialization
Citations

This map shows the geographic impact of Dean Messing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Messing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Messing more than expected).

Fields of papers citing papers by Dean Messing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dean Messing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Messing. The network helps show where Dean Messing may publish in the future.

Co-authorship network of co-authors of Dean Messing

This figure shows the co-authorship network connecting the top 25 collaborators of Dean Messing. A scholar is included among the top collaborators of Dean Messing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean Messing. Dean Messing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Ramaiah, Lila, et al.. (2024). Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route. The AAPS Journal. 26(3). 60–60. 4 indexed citations
2.
Su, Zhenwei, Jonathan Brooks, Jeffrey W. Pelker, et al.. (2023). Studies with neutralizing antibodies suggest CXCL8-mediated neutrophil activation is independent of C-C motif chemokine receptor-like 2 (CCRL2) ligand binding function. PLoS ONE. 18(1). e0280590–e0280590. 3 indexed citations
3.
4.
Jones, Hannah M., John Tolsma, Zhiwei Zhang, et al.. (2020). A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics. CPT Pharmacometrics & Systems Pharmacology. 9(9). 534–541. 12 indexed citations
5.
Neelakantan, Srividya, Barry S. Oemar, Natalie Rath, et al.. (2020). Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study. Clinical Pharmacology in Drug Development. 10(3). 307–316. 10 indexed citations
6.
Benson, Micah J., David von Schack, Sean Keegan, et al.. (2014). Modeling the Clinical Phenotype of BTK Inhibition in the Mature Murine Immune System. The Journal of Immunology. 193(1). 185–197. 19 indexed citations
7.
Li, Xing, Balekudru Devadas, Rajesh Devraj, et al.. (2011). Discovery and Characterization of Atropisomer PH‐797804, a p38 MAP Kinase Inhibitor, as a Clinical Drug Candidate. ChemMedChem. 7(2). 273–280. 32 indexed citations
8.
Devadas, Balekudru, Shaun R. Selness, Lei Xing, et al.. (2011). Substituted N-aryl-6-pyrimidinones: A new class of potent, selective, and orally active p38 MAP kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(13). 3856–3860. 19 indexed citations
9.
10.
Walker, John K., Shaun R. Selness, Rajesh Devraj, et al.. (2010). Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorganic & Medicinal Chemistry Letters. 20(8). 2634–2638. 19 indexed citations
11.
Gallavan, R. H., et al.. (2009). Effect of compound plate composition on measurement of hERG current IC50 using PatchXpress. Journal of Pharmacological and Toxicological Methods. 60(1). 39–44. 20 indexed citations
12.
Hope, Heidi R., Gary D. Anderson, Barry Burnette, et al.. (2009). Anti-Inflammatory Properties of a Novel N-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation. Journal of Pharmacology and Experimental Therapeutics. 331(3). 882–895. 46 indexed citations
13.
Sunyer, T., Olga V. Nemirovskiy, Steven L. Settle, et al.. (2008). A3 TRANSLATIONAL PHARMACOLOGY STRATEGY TO EVALUATE MMP-13 INHIBITORS FOR THE TREATMENT OF OA; USE OF BIOMARKERS. Osteoarthritis and Cartilage. 16. S14–S14. 1 indexed citations
14.
Messing, Dean, et al.. (2005). Predicting drug-drug interactions in drug discovery: where are we now and where are we going?. PubMed. 8(1). 51–8. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa Borges-Marcucci Breakdown of academic impact, for papers by Daigo Asano Breakdown of academic impact, for papers by Janice Darlington Breakdown of academic impact, for papers by Denise M. Wilcox Breakdown of academic impact, for papers by Shaun R. Selness Breakdown of academic impact, for papers by Elena Dneprovskaia Breakdown of academic impact, for papers by Hailin Chen Breakdown of academic impact, for papers by Chengcan Yang Breakdown of academic impact, for papers by Ellen van der Aar Breakdown of academic impact, for papers by Mary D. Adrian
Rankless by CCL
2026